Sluicebox Friday, 08/07/20 09:59:19 AM Re: None Post # of 8038 Cellectar can beat that ! Belantamab just approved for R/R MM with 4 prior lines of therapy including immunomodulatory drug (IMiD), a proteasome inhibitor, and an anti-CD38 antibody, with ORR/PFS which I believe CLR-131 will match and with a much better AE profile. Top sales estimate 2026 $1,5B based on current indications/trials, but a lot of new indications could be added down the line for Belantamab.